Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey J Lindeman

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
The EMBO Journal|April 11, 2025
Fibroblast hierarchy dynamics during mammary gland morphogenesis and tumorigenesisRosa Pascual, Jinming Cheng, Amelia H De Smet, et al.
Nature Medicine|August 4, 2009
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersElgene Lim, François Vaillant, Di Wu, et al.
International Journal of Cancer|August 14, 2009
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative statusNiamh C Murphy, Andrew V Biankin, Ewan K A Millar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2020
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast CancerJames R Whittle, François Vaillant, Elliot Surgenor, et al.
Nature Cell Biology|January 12, 2024
Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriersRachel Joyce, Rosa Pascual, Luuk Heitink, et al.
Science Translational Medicine|August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerDelphine Merino, James R Whittle, François Vaillant, et al.
Ebiomedicine|March 9, 2026
Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classificationCristina Fortuno, Jia Zhang, Lambros T Koufariotis, et al.
Nature Communications|January 25, 2019
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancerStefano Annunziato, Julian R de Ruiter, Linda Henneman, et al.
Nature Medicine|June 1, 2024
Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trialToru Mukohara, Yeon Hee Park, David Sommerhalder, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
The EMBO Journal|April 11, 2025
Fibroblast hierarchy dynamics during mammary gland morphogenesis and tumorigenesisRosa Pascual, Jinming Cheng, Amelia H De Smet, et al.
Nature Medicine|August 4, 2009
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersElgene Lim, François Vaillant, Di Wu, et al.
International Journal of Cancer|August 14, 2009
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative statusNiamh C Murphy, Andrew V Biankin, Ewan K A Millar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2020
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast CancerJames R Whittle, François Vaillant, Elliot Surgenor, et al.
Nature Cell Biology|January 12, 2024
Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriersRachel Joyce, Rosa Pascual, Luuk Heitink, et al.
Science Translational Medicine|August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerDelphine Merino, James R Whittle, François Vaillant, et al.
Ebiomedicine|March 9, 2026
Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classificationCristina Fortuno, Jia Zhang, Lambros T Koufariotis, et al.
Nature Communications|January 25, 2019
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancerStefano Annunziato, Julian R de Ruiter, Linda Henneman, et al.
Nature Medicine|June 1, 2024
Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trialToru Mukohara, Yeon Hee Park, David Sommerhalder, et al.
Pageof 17